A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Inclusion Criteria:

- Have SCD [homozygous sickle cell (HbSS) or hemoglobin (HbS) Beta^0 thalassemia]

- Are participants with SCD who have had ≥2 episodes of vaso-occlusive crisis (VOC) in
the past year

- Have a body weight ≥19 kilograms (kg) and are ≥2 and <18 years of age, inclusive at
the time of screening

- If participants are ≥2 and ≤16 years of age, must have had a transcranial Doppler
within the last year

Exclusion Criteria:

- History of: transient ischemic attack (TIA)/ ischemic or hemorrhagic stroke, severe
head trauma, intracranial hemorrhage, intracranial neoplasm, arteriovenous
malformation, or aneurysm

- History of abnormal or conditional [velocity in middle or anterior cerebral, or
internal carotid artery ≥170 centimeter per second (cm/sec)] transcranial Doppler
within the last year

- History of, or are undergoing treatment with, chronic red blood cell (RBC)
transfusion therapy

- Are at an increased risk for bleeding complications

- Are receiving chronic treatment with nonsteroidal anti-inflammatory drug (NSAID)s and
cannot be switched to another analgesic